X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3978) 3978
Publication (256) 256
Book Review (96) 96
Newsletter (86) 86
Newspaper Article (52) 52
Book Chapter (15) 15
Magazine Article (11) 11
Trade Publication Article (2) 2
Conference Proceeding (1) 1
Data Set (1) 1
Dissertation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
adalimumab (3469) 3469
humans (2903) 2903
index medicus (2389) 2389
infliximab (1936) 1936
female (1797) 1797
male (1685) 1685
adult (1408) 1408
middle aged (1372) 1372
etanercept (1262) 1262
tumor necrosis factor-alpha - antagonists & inhibitors (1250) 1250
treatment outcome (1199) 1199
rheumatoid arthritis (997) 997
rheumatology (982) 982
antibodies, monoclonal - therapeutic use (875) 875
arthritis, rheumatoid - drug therapy (873) 873
antibodies, monoclonal, humanized (719) 719
antirheumatic agents - therapeutic use (714) 714
therapy (706) 706
aged (694) 694
psoriasis (656) 656
drug therapy (653) 653
dermatology (624) 624
care and treatment (622) 622
gastroenterology & hepatology (582) 582
efficacy (576) 576
rheumatoid-arthritis (565) 565
double-blind (552) 552
antibodies, monoclonal, humanized - therapeutic use (541) 541
methotrexate (533) 533
arthritis (519) 519
dosage and administration (513) 513
severity of illness index (490) 490
safety (477) 477
antibodies, monoclonal - adverse effects (473) 473
pharmacology & pharmacy (473) 473
crohn disease - drug therapy (467) 467
crohn's disease (453) 453
tumor necrosis factor (446) 446
psoriasis - drug therapy (445) 445
antibodies, monoclonal - administration & dosage (444) 444
retrospective studies (421) 421
young adult (419) 419
antirheumatic agents - adverse effects (415) 415
anti-inflammatory agents - therapeutic use (408) 408
crohns-disease (403) 403
adalimumab - therapeutic use (401) 401
antirheumatic agents - administration & dosage (393) 393
medicine & public health (386) 386
inflammatory-bowel-disease (385) 385
tumor necrosis factor-tnf (379) 379
analysis (378) 378
drug therapy, combination (368) 368
immunoglobulin g - therapeutic use (365) 365
receptors, tumor necrosis factor - therapeutic use (359) 359
monoclonal antibodies (358) 358
adolescent (344) 344
risk factors (337) 337
patients (325) 325
inflammatory bowel disease (320) 320
research (313) 313
antibodies, monoclonal, humanized - administration & dosage (306) 306
antibodies, monoclonal, humanized - adverse effects (305) 305
rheumatoid factor (298) 298
adalimumab - administration & dosage (296) 296
ulcerative colitis (294) 294
drug administration schedule (293) 293
time factors (284) 284
disease (278) 278
follow-up studies (277) 277
immunology (276) 276
anti-inflammatory agents - administration & dosage (273) 273
clinical trials (273) 273
complications and side effects (259) 259
dose-response relationship, drug (258) 258
trial (247) 247
methotrexate - therapeutic use (242) 242
certolizumab pegol (237) 237
abridged index medicus (236) 236
remission induction (235) 235
monoclonal-antibody (232) 232
double-blind method (231) 231
remission (226) 226
placebo-controlled trial (221) 221
anti-inflammatory agents - adverse effects (219) 219
prospective studies (219) 219
internal medicine (217) 217
health aspects (215) 215
immunosuppressive agents - therapeutic use (213) 213
infliximab - therapeutic use (213) 213
antibodies (212) 212
studies (206) 206
adalimumab - adverse effects (205) 205
tumor necrosis factor-alpha - immunology (203) 203
patient outcomes (202) 202
biologics (201) 201
medical research (201) 201
quality of life (201) 201
inflammation (200) 200
necrosis-factor-alpha (198) 198
tnf inhibitors (194) 194
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3963) 3963
German (43) 43
French (33) 33
Spanish (29) 29
Japanese (18) 18
Russian (13) 13
Hungarian (11) 11
Korean (11) 11
Italian (7) 7
Danish (4) 4
Polish (2) 2
Turkish (2) 2
Arabic (1) 1
Chinese (1) 1
Croatian (1) 1
Romanian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 06/2014, Volume 370, Issue 25, pp. 2377 - 2386
In patients with rheumatoid arthritis, tofacitinib was associated with greater reductions in signs and symptoms than methotrexate. Herpes zoster infections and... 
MEDICINE, GENERAL & INTERNAL | MODIFYING ANTIRHEUMATIC DRUGS | ADALIMUMAB | RECOMMENDATIONS | COMBINATION THERAPY | JOINT DAMAGE | DISEASE | PLUS METHOTREXATE | DOUBLE-BLIND | ETANERCEPT | CP-690,550 | Herpes Zoster - etiology | Antirheumatic Agents - administration & dosage | Arthritis, Rheumatoid - blood | Cholesterol - blood | Humans | Middle Aged | Male | Protein Kinase Inhibitors - adverse effects | Arthritis, Rheumatoid - complications | Dose-Response Relationship, Drug | Janus Kinase 3 - antagonists & inhibitors | Arthritis, Rheumatoid - drug therapy | Pyrroles - administration & dosage | Antirheumatic Agents - adverse effects | Pyrroles - adverse effects | Adult | Female | Piperidines - administration & dosage | Double-Blind Method | Administration, Oral | Pyrimidines - administration & dosage | Methotrexate - adverse effects | Protein Kinase Inhibitors - administration & dosage | Piperidines - adverse effects | Pyrimidines - adverse effects | Creatinine - blood | Methotrexate - administration & dosage | Care and treatment | Dosage and administration | Tofacitinib | Comparative analysis | Methotrexate | Rheumatoid arthritis | Creatinine | Herpes zoster | C-reactive protein | Kinases | Joint diseases | E.S.R | Lymphoma | Sedimentation | Cholesterol | Pain | Rheumatism | Janus kinase | Drug therapy | Pharmaceuticals | Cancer
Journal Article
Lancet, The, ISSN 0140-6736, 2017, Volume 390, Issue 10093, pp. 457 - 468
Summary Background Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. The Oral Rheumatoid Arthritis triaL (ORAL) Strategy... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | MODIFYING ANTIRHEUMATIC DRUGS | NECROSIS-FACTOR | PLACEBO | JANUS KINASE INHIBITOR | INADEQUATE RESPONSE | LONG-TERM SAFETY | PLUS METHOTREXATE | AMERICAN-COLLEGE | OPEN-LABEL | COMBINATION | Antirheumatic Agents - administration & dosage | Humans | Middle Aged | Male | Methotrexate - therapeutic use | Adalimumab - adverse effects | Arthritis, Rheumatoid - drug therapy | Pyrroles - administration & dosage | Antirheumatic Agents - adverse effects | Pyrroles - adverse effects | Adult | Female | Drug Therapy, Combination | Pyrroles - therapeutic use | Antirheumatic Agents - therapeutic use | Severity of Illness Index | Piperidines - administration & dosage | Double-Blind Method | Drug Administration Schedule | Administration, Oral | Pyrimidines - administration & dosage | Treatment Outcome | Methotrexate - adverse effects | Adalimumab - therapeutic use | Adalimumab - administration & dosage | Piperidines - therapeutic use | Pyrimidines - therapeutic use | Piperidines - adverse effects | Pyrimidines - adverse effects | Methotrexate - administration & dosage | Rheumatoid factor | Care and treatment | Analysis | Clinical trials | Arthritis | Pharmaceutical industry | Methotrexate | Rheumatology | Patients | Studies | Rheumatoid arthritis | Monoclonal antibodies | Rheumatism | TNF inhibitors | Janus kinase | Tumor necrosis factor-TNF | Safety | Drug therapy | Drug dosages
Journal Article
Journal Article
Lancet, The, ISSN 0140-6736, 2015, Volume 386, Issue 10006, pp. 1825 - 1834
Journal Article
Journal Article
Journal Article
Annals of the Rheumatic Diseases, ISSN 0003-4967, 01/2014, Volume 73, Issue 1, pp. 132 - 137
Background The role of co-medication with tumour necrosis factor inhibitors (TNFi) is well established in rheumatoid arthritis and ankylosing spondylitis. In... 
RHEUMATOID-ARTHRITIS | CONTROLLED-TRIAL | EFFICACY | TNF-alpha | SAFETY | ANKYLOSING-SPONDYLITIS | RHEUMATOLOGY | RECOMMENDATIONS | DOUBLE-BLIND | THERAPIES | Methotrexate | ETANERCEPT | INFLIXIMAB | Psoriatic Arthritis | Antirheumatic Agents - administration & dosage | Humans | Methotrexate - pharmacokinetics | Middle Aged | Antibodies, Monoclonal - adverse effects | Male | Antibodies, Monoclonal, Humanized - administration & dosage | Etanercept | Infliximab | Antibodies, Monoclonal, Humanized - pharmacokinetics | Arthritis, Psoriatic - drug therapy | Antirheumatic Agents - adverse effects | Adult | Female | Drug Therapy, Combination | Receptors, Tumor Necrosis Factor - metabolism | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal - pharmacokinetics | Receptors, Tumor Necrosis Factor - administration & dosage | Treatment Outcome | Immunoglobulin G - administration & dosage | Immunoglobulin G - adverse effects | Methotrexate - adverse effects | Antibodies, Monoclonal - administration & dosage | Antirheumatic Agents - pharmacokinetics | Methotrexate - administration & dosage | Adalimumab | Longitudinal Studies | Tumor Necrosis Factor-alpha - antagonists & inhibitors | Immunoglobulin G - metabolism | Usage | Dosage and administration | Drug therapy | Tumor necrosis factor inhibitors | Psoriatic arthritis | Studies | Variables | Immunoglobulins | Rheumatology | TNF inhibitors | Arthritis | Regression analysis | Multivariate analysis
Journal Article